Pacific Edge FY26 revenue halves to NZ$11.5 million amid Medicare coverage loss

Capital Raise Targets Cash Runway Amid Medicare Reimbursement Setback

Pacific Edge (NZX:ASX: PEB) has kicked off a NZ$24 million capital raising to steady the ship after a sharp revenue decline caused by Medicare’s withdrawal of coverage for its flagship Cxbladder test. The raise consists of an NZ$18 million placement to institutional investors and a NZ$6 million retail offer for existing New Zealand shareholders, priced at NZ$0.170 per share, a slight discount to recent trading.

The company’s unaudited FY26 results reveal operating revenue halved to NZ$11.5 million from NZ$21.8 million in FY25, driven by a 21.4% drop in US test volumes following Medicare’s non-coverage determination in 2025. Pacific Edge’s US laboratory throughput fell to 18,784 tests from 23,885, compounded by the transition from Cxbladder Detect to Triage and the challenge of selling a test without Medicare reimbursement. Meanwhile, volumes in the Asia-Pacific region grew modestly by 7.9%.

Medicare Draft Policy Expected to Unlock Revenue Growth

Central to Pacific Edge’s turnaround plan is the anticipated release of a draft Local Coverage Determination (LCD) for hematuria evaluation by Novitas, the Medicare contractor overseeing its US lab, expected before September 2026. This draft policy could reintroduce coverage for Cxbladder Triage and potentially Triage Plus, distinguishing hematuria patients eligible for testing from cancer patients excluded under the current non-coverage LCD.

Following the draft’s publication, Pacific Edge plans to seek claim-by-claim reimbursement supported by medical necessity documentation, aiming to boost revenue and reduce the company’s average monthly cash burn below NZ$2.5 million in FY27, down from NZ$2.85 million in FY26. The final LCD could take up to a year after the draft, with a minimum 45-day notice and comment period and another 45 days before becoming effective.

Cost Containment Measures Temper Losses but Cash Reserves Shrink

Despite the revenue hit, Pacific Edge has aggressively cut costs, lowering total expenses to NZ$49.3 million from NZ$54.6 million in FY25. Capital conservation initiatives reduced average monthly cash burn by 27.7% in the second half of FY26 to NZ$2.4 million. However, net losses widened to NZ$35.7 million, up from NZ$29.9 million the previous year, and cash and equivalents fell sharply to NZ$7.8 million at 31 March 2026 from NZ$22.1 million six months earlier.

Chairman Simon Flood emphasised the company’s position as a first mover in bladder cancer diagnostics, backed by robust clinical evidence and guideline endorsements, including a Grade A rating from the American Urological Association for Cxbladder Triage. Flood and all directors intend to participate in the capital raise, signalling confidence in the company’s path to regaining Medicare coverage and commercial growth.

Commercial and Clinical Momentum Hinges on Medicare Outcome

Pacific Edge’s CEO, Dr Peter Meintjes, highlighted the company’s opportunity to entrench its leadership in urine biomarker diagnostics with the upcoming Medicare draft LCD. The company is also advancing next-generation tests like Triage Plus, priced at US$1,328 per test, and Surveillance Plus, targeting a CPT-PLA code submission by December 2026 and provisional reimbursement from July 2027.

While Medicare coverage remains uncertain and timelines are controlled by Novitas, the recent Contractor Advisory Committee meeting in February 2026 strongly endorsed urine-based biomarkers, frequently citing Pacific Edge’s peer-reviewed studies. This panel support underpins the company’s optimism but does not guarantee a positive outcome.

Global Market Opportunity and Regional Growth Initiatives

Bladder cancer diagnostics represent a US$10.8 billion global market, with hematuria evaluation as a key growth driver. Pacific Edge’s tests are available in the US, Australasia, Israel, and parts of Asia and South America. The company is developing business in Southeast Asia and Australia, with ongoing efforts to secure hospital contracts and national clinical pathways, notably with Te Whatu Ora in New Zealand.

In the US, partnerships with health systems like Kaiser Permanente Southern California and a pilot study in the Mid-Atlantic region demonstrate real-world clinical and economic value, while commercial payer policies are gradually evolving, with some Blue Cross Blue Shield plans adopting supportive coverage.

Risks and Uncertainties Surround Medicare Re-Coverage and Financial Viability

Pacific Edge faces significant risks, chiefly the uncertainty around Medicare coverage reinstatement. Novitas may delay, alter, or retire the draft LCD, and any adverse changes could materially impact the company’s financial position. The company is currently operating at a cash burn and dependent on successful capital raises and Medicare re-coverage to sustain operations and achieve profitability.

Other risks include competitive pressures in the diagnostics sector, regulatory and reimbursement challenges, potential delays in new product development, and operational risks such as cyber threats and key personnel retention.

The capital raise is not underwritten, adding execution risk. Investors should weigh these factors carefully against the potential upside from a Medicare policy shift and expanding market adoption.